Sandoz awarded $70.6 million in US antitrust case over Remodulin against UTC
MLex Summary: Sandoz Pharmaceuticals was awarded a $70.6 million judgment against United Therapeutics Corp. in a US case accusing UTC of illegally obstructing the release of a generic competitor to the...To view the full article, register now.
Already a subscriber? Click here to view full article